Keywords Not Major Advertising Enforcement Concern, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA says keywords don’t need OPDP’s formal review, but that doesn’t mean they don’t have an opinion about how they’re used.
You may also be interested in...
Gilead’s Sponsored Link For Viread Can’t Prevent Trouble With FDA
Agency cites firm for unapproved claim, not including any risk information, and not submitting link to FDA.
AstraZeneca Pulls Twitter Ads, Showing Risks Of Expansive Social Media Platforms
Company thought sponsored messages on AP’s feed were unbranded, but realized drug name showed up in expanded tweet. Did intricacies of the platform produce an inadvertent violation?
FDA’s Biggest DTC Advertising Study Eyes Online Promotion
The agency has 11 research projects under way, including a $2 million study of online Rx drug promotion; pharma spending on direct-to-consumer advertising declined in 2012 with biggest spends on Cymbalta and Cialis ads.